Please assess the completion status of the following clinical trial:

Trial Title: A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has diagnosed cancer of pancreas with biopsy and/or radiography, with a life expectancy of at least 5 months at screening~* Participant's pancreatic cancer must involve the head and/or neck of the pancreas~* Confirmed exocrine pancreatic insufficiency (EPI) as evidenced by fecal elastase-1 (FE-1) ≤ 150 µg/g stool at screening~* A positive Sudan stain for participants without history of fat malabsorption (fat malabsorption is defined as clinical steatorrhea, or measured stool fat \> 7 g/day, or positive stool results by Sudan stain) within 1 week of screening -- Positive stool results are defined as increased level of neutral OR total fats~Exclusion Criteria:~* Participant has neuroendocrine pancreatic cancer~* Participant has fibrosing colonopathy~* Participant has any other malignancy within 1 year of screening~* Participant has uncontrolled gout, including those with a recent flare within 60 days of screening~* Participant has other significant organ or bone marrow abnormality within 60 days of screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Resected Participants Receiving Low Dose (12,000/6,000 units lipase) Pancrelipase (Type: EXPERIMENTAL): Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
- Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase (Type: EXPERIMENTAL): Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
- Non-Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase (Type: EXPERIMENTAL): Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks.

Based on this trial design, predict the completion outcome and termination type (if applicable).